Clinical Outcome of a Novel Anti-CD6 Biologic Itolizumab in Patients of Psoriasis with Comorbid Conditions

Singh, Vinay Kumar

doi:10.1155/2016/1316326

Cited by 6 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The safety of itolizumab was also established in a case series of five patients reported by Nott et al,13 a case series of seven patients by Singh,14 a case series of 20 patients by Parthasaradhi,15 a case series of 155 patients by Parthasaradhi et al,16 a case series of five patients by Pai and Pai,17 a case report presented by Trasi et al,18 a case report by Gupta et al,19 and a case report by Budamakuntla et al20 In all the clinical studies and individual case reports or case series, itolizumab was safe and well tolerated (Tables 2 and 3).…”

Section: Safety and Efficacy Of Itolizumab For Psoriasis In Indian Pamentioning

confidence: 85%

<p>Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India</p>

Budamakuntla

Shree-Lakshmi

Bansal

et al. 2019

PTT

View full text Add to dashboard Cite

Psoriasis is a chronic, debilitating, immune-mediated, systemic inflammatory disease affecting mainly skin, nails, and joints. Several therapeutic modalities are available depending on the severity of the disease. Long-term use of these drugs results in unwanted effects and toxicities. Recently, itolizumab, a humanized monoclonal immunoglobulin G1 antibody to CD6, has shown appreciable clinical effects and safety profile in patients with moderate-to-severe chronic plaque psoriasis. A literature search was conducted using the keywords “anti-CD6”, “psoriasis”, “phase trials”, “case series”, and “case reports”. The data from all studies conducted in India on efficacy of itolizumab in psoriasis and published before September 2017 were collected. This article provides an overview of the clinical data obtained in these published articles. Itolizumab has immunomodulatory and anti-inflammatory effects. It is efficacious and provides a good duration of remission, and hence represents a new biological agent that could be added to the therapeutic armamentarium of psoriasis.

show abstract

Section: Safety and Efficacy Of Itolizumab For Psoriasis In Indian Pamentioning

confidence: 85%

<p>Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India</p>

Budamakuntla

Shree-Lakshmi

Bansal

et al. 2019

PTT

View full text Add to dashboard Cite

show abstract

“…Itolizumab : This is an anti-CD6 humanized monoclonal IgG1 antibody which acts upstream by inhibiting the co-stimulation of T cells, resulting in decreased release of signature cytokines of Th1 and Th17 cells 13 14 . Sponsored by an Indian pharmaceutical company, this open-label, Phase 2, randomized, parallel-group, active controlled multicenter trial is being conducted on 30 patients with moderate-to-severe COVID-19 to assess mortality rates and possible effects on the dreaded cytokine release syndrome (CTRI/2020/05/024959).…”

Section: Drug Trialsmentioning

confidence: 99%

Emerging trends from COVID-19 research registered in the Clinical Trials Registry - India

Rao¹,

Juneja

Maulik

et al. 2021

Indian Journal of Medical Research

View full text Add to dashboard Cite

Since the beginning of the year, the deadly coronavirus pandemic, better known as coronavirus disease 2019 (COVID-19), brought the entire world to an unprecedented halt. In tandem with the global scenario, researchers in India are actively engaged in the conduct of clinical research to counter the pandemic. This review attempts to provide a comprehensive overview of the COVID-19 research in India including design aspects, through the clinical trials registered in the Clinical Trials Registry - India (CTRI) till June 5, 2020. One hundred and twenty two registered trials on COVID-19 were extracted from the CTRI database. These trials were categorized into modern medicine (n=42), traditional medicine (n=67) and miscellaneous (n=13). Of the 42 modern medicine trials, 28 were on repurposed drugs, used singly (n=24) or in combination (n=4). Of these 28 trials, 23 were to evaluate their therapeutic efficacy in different severities of the disease. There were nine registered trials on cell- and plasma-based therapies, two phytopharmaceutical trials and three vaccine trials. The traditional medicine trials category majorly comprised Ayurveda (n=45), followed by homeopathy (n=14) and others (n=8) from Yoga, Siddha and Unani. Among the traditional medicine category, 31 trials were prophylactic and 36 were therapeutic, mostly conducted on asymptomatic or mild-to-moderate COVID-19 patients. This review would showcase the research being conducted on COVID-19 in the country and highlight the research gaps to steer further studies.

show abstract

“…We generated ApoE/CD6 DKO mice to address the role of CD6 in cardiovascular disease given the recent focus of CD6 as a therapeutic target for the treatment of several autoimmune diseases [ 16 , 19 , 22 – 25 ]. We hypothesized that the DKO mice would have larger lesions due to decreased B1a cells and natural IgM.…”

Section: Main Textmentioning

confidence: 99%

CD6 expression has no effect on atherosclerosis in apolipoprotein E-deficient mice

et al. 2018

View full text Add to dashboard Cite

ObjectiveTo determine if deficiency of CD6, a cell surface protein on lymphocytes that alters natural antibody production, increases atherosclerosis in ApoE-deficient mice fed a chow or a western-type diet.ResultsWe compared cholesterol levels, IgM, B1a cells, and aortic root lesion areas in ApoE-deficient vs. CD6/ApoE double deficient mice. Feeding the high-fat western type diet increased all parameters, except for B1a cell numbers decreased. Sex also had an effect on many parameters with males having increased body weights, higher high density lipoprotein cholesterol, higher B1a cells, but smaller atherosclerotic lesions if chow fed mice; however, this sex effect on atherosclerosis was absent in mice fed the western-type diet. CD6 deficiency had no effect on atherosclerosis in both male and female mice on either diet. Thus, loss of CD6 on lymphocytes did not lead to expected reductions in B1a cells and protective IgM levels, and in turn did not alter atherosclerosis in mice.

show abstract

Clinical Outcome of a Novel Anti-CD6 Biologic Itolizumab in Patients of Psoriasis with Comorbid Conditions

Cited by 6 publications

References 8 publications

<p>Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India</p>

<p>Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India</p>

Emerging trends from COVID-19 research registered in the Clinical Trials Registry - India

CD6 expression has no effect on atherosclerosis in apolipoprotein E-deficient mice

Contact Info

Product

Resources

About